UMS United Medical Systems International AG: Final Payment of Liquidation Proceeds to Shareholders

UMS United Medical Systems International AG / Key word(s): Dividend/Dividend

UMS United Medical Systems International AG: Final Payment of Liquidation Proceeds to Shareholders

12-Oct-2018 / 10:24 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


UMS United Medical Systems International AG i. L.:

Final Payment of Liquidation Proceeds to Shareholders

Hamburg, October 12, 2018. The liquidator of UMS United Medical Systems International AG i. L. (UMS, ISIN DE 0005493654 / WKN 549365) (the “Company”) has made a final payment of liquidation proceeds to the Company’s shareholders, with the consent of the Supervisory Board. An amount of EUR 0.61 will be distributed to each bearer share of no-par-value stock of the Company. The distribution will be made on October 22, 2018 by the custodian banks via Clearstream Banking AG.

Any taxes owed on the final payment at the shareholder level will be determined on the basis of the individual shareholder’s situation (e.g. whether the shares are held as part of their personal assets or as part of their business assets). The final payment is a repayment of par value.

The Company in Brief

UMS International AG is a stock corporation listed in the Prime Standard of Deutsche Börse AG. On August 14,2014, the Company sold its interest in United Medical Systems (DE), Inc. and thus sold its entire assets. The Company’s Extraordinary General Meeting on September 25, 2014 approved the transfer of assets and liabilities. The agreement was finalized on November 11, 2014. Upon completion of the transfer of assets, the company’s corporate purpose was changed to the management of its own assets.

At their annual meeting on April 27, 2015, the shareholders resolved to dissolve the company on April 30, 2015.

Contact

Christian Möller, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail:

investor@umsag.com


12-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: UMS United Medical Systems International AG
Borsteler Chaussee 53
22453 Hamburg
Germany
Phone: +49 (0)40 – 500 177 – 00
Fax: +49 (0)40 – 500 177 – 77
E-mail: investor@umsag.com
Internet: www.umsag.com
ISIN: DE0005493654
WKN: 549365
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

UMS United Medical Systems International AG: UMS AG reports on the liquidation period from May 1 to August 31, 2018 (final liquidation financial statements)

DGAP-News: UMS United Medical Systems International AG / Key word(s): Interim Report/Interim Report

12.10.2018 / 10:00

The issuer is solely responsible for the content of this announcement.


UMS AG reports on the liquidation period from May 1 to August 31, 2018 (final liquidation financial statements)

Hamburg, October 12, 2018. UMS United Medical Systems International AG i. L. (UMS, ISIN DE 0005493654 / WKN 549365) has reported on the liquidation period from May 1, 2018 to August 31, 2018 (final liquidation financial statements).

The Company’s final legal dispute was settled in that liquidation period, as the Company entered into a settlement agreement with the opposing party. This provided the Company with a settlement amount of EUR 355k, with the earnings per share amounting to EUR 7 cents per share. The bank balances amounted to EUR 2,733k or 63 cents per share, up from EUR 2,704k at the beginning of the liquidation period. Equity increased to EUR 2,639k or 62 cents per share, from EUR 2,343k or 55 cents per share at the beginning of the liquidation period.

The full report is available on the Company’s website at www.umsag.com

The Company in Brief

UMS International AG is a stock corporation listed in the Prime Standard of Deutsche Börse AG. On August 14,2014, the Company sold its interest in United Medical Systems (DE), Inc. and thus sold its entire assets. The Company’s Extraordinary General Meeting on September 25, 2014 approved the transfer of assets and liabilities. The agreement was finalized on November 11, 2014. Upon completion of the transfer of assets, the company’s corporate purpose was changed to the management of its own assets.

At their annual meeting on April 27, 2015, the shareholders resolved to dissolve the company on April 30, 2015.

Contact

Christian Möller, Tel: (040) 50 01 77-00, Fax: (040) 50 01 77-77, E-Mail:
investor@umsag.com


12.10.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: UMS United Medical Systems International AG
Borsteler Chaussee 53
22453 Hamburg
Germany
Phone: +49 (0)40 – 500 177 – 00
Fax: +49 (0)40 – 500 177 – 77
E-mail: investor@umsag.com
Internet: www.umsag.com
ISIN: DE0005493654
WKN: 549365
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

Heidelberg Pharma AG / Key word(s): Alliance

Heidelberg Pharma AG: Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

11-Oct-2018 / 11:59 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.


Ad hoc announcement – Inside information pursuant to Article 17 MAR

Partner Magenta Therapeutics Exercises Option To Further Develop a Target Molecule as Antibody Targeted Amanitin Conjugate

Ladenburg, Germany, 11 October 2018 – Heidelberg Pharma AG (FSE: WL6) today announced that its partner Magenta Therapeutics (NASDAQ: MGTA), Cambridge, MA, USA, exercises its option to further develop a target molecule, and will now continue the development of an Antibody Targeted Amanitin Conjugate based on the target molecule within an exclusive licensing.

In March 2018, both companies signed an exclusive multi-target research agreement under which Magenta gained access to Heidelberg Pharma’s Amanitin toxin-linker platform technology. Proprietary antibodies generated from Magenta’s stem cell platform for up to four exclusive targets were used to generate new ATACs (“Antibody Targeted Amanitin Conjugates”) using Heidelberg Pharma’s proprietary ATAC technology.

Today, 11 October, Magenta has sent us its declaration on the exercise of its option to exclusively license the worldwide development and commercialization rights to a target molecule and the resulting product candidates. Heidelberg Pharma receives an undisclosed milestone payment in return. Furthermore, Heidelberg Pharma would be eligible to receive clinical development, regulatory and sales-related milestone payments.

+++ End of the ad hoc announcement +++


Information and Explanation of the Issuer to this News:

About Heidelberg Pharma
Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. ATAC technology is the core activity of the subsidiary Heidelberg Pharma Research GmbH.

Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R), while RENCAREX(R) is available for out-licensing and further development. The Company is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at www.heidelberg-pharma.com.

About Magenta Therapeutics
Magenta Therapeutics (NASDAQ: MGTA) is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Massachusetts. Since June 2018, Magenta is listed on NASDAQ. For more information, please visit www.magentatx.com.

About Bone Marrow Transplant
Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit.

Contact
Heidelberg Pharma AG
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
Email: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg
IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Email: katja.arnold[at]mc-services.eu
 

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as ‘estimates’, ‘believes’, ‘expects’, ‘may’, ‘will’ ‘should’ ‘future’, ‘potential’ or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.


11-Oct-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Heidelberg Pharma AG
Schriesheimer Str. 101
68526 Ladenburg
Germany
Phone: +49 (0)89 41 31 38 – 0
Fax: +49 (0)89 41 31 38 – 99
E-mail: investors@hdpharma.com
Internet: www.heidelberg-pharma.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange

 
End of Announcement DGAP News Service

show this

Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-T

goetzpartners securities Limited

28-Sep-2018 / 07:39 GMT/BST


Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 28th September 2018 @ 7.17am (London time).

 

Actinium Pharmaceuticals Inc (ATNM-US): Improving access to CAR-T
Recommendation: OUTPERFORM
Target Price: USD$4.00
Current Price: USD$0.76 (COB on 27th September 2018)

KEY TAKEAWAY

With its molecular-targeted radio-therapy Iomab-B showing promise and in a pivotal Phase III for bone marrow transplant, Actinium has initiated a programme to use lower dose (Iomab-ACT) to boost safety and efficacy of the much-vaunted CAR-T therapy in blood cancers. While the tens of billions USD spent on CAR-T assets highlight the potential, the extreme cost and safety concerns surrounding CAR-T have so far held back uptake of the two marketed products Kymriah (Novartis) and Yescarta (Kite Pharma / Gilead). Based on previous data, Actinium believes that replacing the current toxic pre-CAR-T conditioning regimen with targeted radiotherapy could improve patient outcomes, potentially reducing barriers to reimbursement and expanding patient access. Although the true scale of the CAR-T Iomab-ACT opportunity is unclear at this early stage, Actinium’s new initiative further highlights the potential of its molecular-targeted radiotherapy in blood and immune diseases. We maintain and reiterate both our OUTPERFORM recommendation and TP of $4.00 / share as detailed in our initiation report of April 2018.

Benefits of Iomab-ACT over chemo – Successful CAR-T therapy requires depletion of patient lymphocytes prior to treatment. Iomab-ACT therapy promises to provide specific targeting of lymphocytes, including cancer cells, provided by one dose in an out-patient setting. Current fludaribine / cyclophosphamide (“Flu-Cy”) leads to non-specific blood cell depletion as well as other toxicity and requires multiple infusions over a number of days. Iomab-ACT has the potential for better efficacy, safety and convenience.

CAR-T benefits come at a cost – The benefits of the already marketed products Kymriah and Yescarta in helping otherwise hopeless patients beat treatment refractory blood cancers including acute lymphoblastic leukaemia (“ALL”), diffuse large cell lymphoma (“DLCL”) are well known. However, the enormous cost of manufacturing and supplying these personalised therapies (treatment costs approaching $500k) presents a significant barrier to reimbursement.

Improved outcomes could facilitate reimbursement – Given the sky-high cost, payers increasing looking towards outcome-based reimbursement schemes for CAR-T based therapies. The improved safety and efficacy promised by Iomab-ACT compared to existing chemotherapeutic Flu-Cy regimens could facilitate such an outcome-based approach.

Documented safety and efficacy of Iomab – Low dose Iomab has already been shown to deplete lymphocytes and is safe at much greater doses as documented in over 500 patients undergoing pre-bone marrow transplant conditioning. While Actinium has yet to disclose details, a relatively simple dosing trial of Iomab-ACT in combination with CAR-T is in planning by its clinical collaborators.

Providing CAR-T players with freedom to operate – Flu-Cy lymphocyte depletion regimens for CAR-T is covered by a patent filed by Kite Pharma (owned by Gilead). An effective alternative conditioning pathway patented by Actinium could provide other CAR-T players freedom to operate.

Significant upside – The prospect of significant clinical news flow from Actimab in H2/2018E and pivotal readout on Iomab-B suggests significant upside from current levels. As detailed in our initiation report of April 2018, our valuation suggests that Actinium still remains fundamentally undervalued at current levels. Our analysis indicates a current fair value of $2.60 per share rising to $5.00 per share on the back of positive phase 2 data in H2/2018E. We maintain and reiterate both our OUTPERFORM recommendation and target price of $4.00 per share.

Kind regards,

Chris Redhead | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | chris.redhead@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

Click here to see our privacy policy.

 

GPSL has a formal client relationship with Actinium Pharmaceuticals Inc.

GPSL publishes and distributes “Investment” Research and “Corporate Sponsored” Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority (“FCA”). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation (“GDPR“) – if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited (“GPSL”) is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=26b46358-9d60-4488-8ee3-4d544570c416&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

NORTHERN BITCOIN AG LISTED IN STOCK EXCHANGE SEGMENT M:ACCESS OF THE MUNICH STOCK EXCHANGE

DGAP-News: Northern Bitcoin AG / Key word(s): Miscellaneous

28.09.2018 / 07:30

The issuer is solely responsible for the content of this announcement.


NORTHERN BITCOIN AG LISTED IN STOCK EXCHANGE SEGMENT M:ACCESS OF THE MUNICH STOCK EXCHANGE

– Leading Bitcoin miner with climate-neutral mining pool

– High dynamics due to strong Bitcoin distribution

– Rapidly growing operating business

Frankfurt am Main – September 28, 2018 – Northern Bitcoin AG (ISIN: DE000A0SMU87), a technology company specializing in the Bitcoin blockchain infrastructure and operator of its own climate-neutral Bitcoin mining pool, has been listed on the Munich Stock Exchange’s m:access midmarket segment as of today.

“Northern Bitcoin AG’s business is very dynamic. We are developing synchronously with the globally strongly growing Bitcoin blockchain and its first and largest application, the Bitcoin. In order to be one of the world’s first listed companies in this sector to serve the interests and needs of our investors more effectively, the m:access segment of the Munich Stock Exchange is very attractive. With the listing in this segment, we are able to offer our investors greater publicity, which is geared to our rapidly growing operating business,” explains Mathis Schultz, CEO of Northern Bitcoin AG, and emphasizes: “The listing was very structured and effective in close coordination and trusting cooperation with the Munich Stock Exchange. Northern Bitcoin was accompanied by mwb fairtrade Wertpapierhandelsbank”.

“The listing is further proof of the high esteem in which the recognized and rapidly growing segment is held,” says Dr. Marc Feiler, Managing Director of the Munich stock exchange. “With Northern Bitcoin, we have gained an innovative, young company in a very interesting and highly regarded market for m:access”, continues Dr. Feiler. “This shows us that we offer an unbureaucratic and flexible stock exchange in Munich that attracts companies across all industries,” says Dr. Feiler.

m:access is a quality segment of the Munich Stock Exchange’s open market that ensures a high degree of transparency through special admission and follow-up obligations which are closely aligned with the regulated market. It thus stands out from the usual open market. For Northern Bitcoin AG, the analysts’ conferences organized as a follow-up obligation for the issuers in m:access are a further argument for listing in the midmarket segment of the Munich Stock Exchange.

About Northern Bitcoin:
Northern Bitcoin AG is a technology company focused on the Bitcoin blockchain. It is challenging the status quo of Bitcoin mining and redefining it. As a pioneer, it provides Bitcoin and blockchain technology with a sustainable infrastructure. To this end, it operates its own state-of-the-art mining hardware based on renewable energy sources under extremely cost-efficient and secure conditions as well as a self-developed mining pool. The company is headquartered in Frankfurt am Main. Further information under www.northernbitcoin.com

Disclaimer:
This press release does not constitute an offer to sell or the solicitation of an offer to buy or subscribe for any securities of Northern Bitcoin AG and does not constitute a prospectus of Northern Bitcoin AG. The information contained in this press release is not intended to form the basis of any financial, legal, tax or other business decision. Investment or other decisions should not be made solely on the basis of this press release. As with all business and investment matters, please consult qualified professional advice. This release and the information contained herein are not for distribution, directly or indirectly, in or into Canada, Australia or Japan.

Press contact:
Northern Bitcoin AG
Dr. Hans Joachim Dürr
Head of Corporate Communications
Thurn-und-Taxis-Platz 6
60313 Frankfurt
Germany
E-Mail: h.duerr@northernbitcoin.com
Telefon: +49 69 348 752 89

Investor Relations:
Sven Pauly
E-Mail: ir@northernbitcoin.com
Telefon: +49 89 89 82 72 27


28.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Northern Bitcoin AG
Thurn-und-Taxis-Platz 6
60313 Frankfurt/Main
Germany
Phone: +49 69 34 87 52 25
E-mail: info@northernbitcoin.com
Internet: www.northernbitcoin.com
ISIN: DE000A0SMU87
WKN: A0SMU8
Listed: Regulated Unofficial Market in Munich

 
End of News DGAP News Service

show this

Shineway was selected into the pilot list of Yunnan Province’s TCM formula granules research

EQS-News / 28/09/2018 / 10:52 UTC+8

Shineway was selected into the pilot list of Yunnan Province’s TCM formula granules research

Yunnan Shineway Spirin Pharmaceutical, a wholly-owned subsidiary of Shineway, was selected into the pilot list of Yunnan Province’s TCM formula granules research, and received financial support from Yunnan Provincial Project Fund. Shineway’s production facilities in the Chuxiong Prefecture of Yunnan Province is also expected to be completed by October this year to add another 1 billion bags (grams) of TCM formula granules capacity. These latest developments signify that Shineway’s venturing into the Yunnan Province’s TCM formula granules market has officially commenced.

Other Shineway news:

1. Shineway has recently entered into strategic cooperation agreements with a number of online clinics and online retail pharmacies, including “WeDoctor”, an online healthcare service provider; “Ehaoyao.com”, the online pharmacy of Jointown Pharmaceutical; and “1 Pharmacy”, the online pharmacy of 111 Inc., to position its “internet + medicine” industry value chain.

For more information, please contact Mr. Randy Hung, Director of Investor Relations via email randyhung@shineway.com.hk

 

Document: http://n.eqs.com/c/fncls.ssp?u=MCMRJCSAAR
Document title: Shineway was selected into the pilot list of Yunnan Province’s TCM formula granules research

28/09/2018 Dissemination of a Marketing Press Release, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

show this

Immutep Limited (IMM-AU): Key takeaways from investor meetings in London

goetzpartners securities Limited

27-Sep-2018 / 10:59 GMT/BST


Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

Published to the market and investors on 27th September 2018 @ 10.16am (London time).

 

Immutep Limited (IMM-AU): Key takeaways from investor meetings in London
Recommendation: OUTPERFORM
Target Price: AUD0.078
Current Price: AUD0.047 (COB on 27th September 2018)

KEY TAKEAWAY

In this flash note we summarise key areas of focus at investor meetings we hosted in London and further take the opportunity to flag the clinical trial collaboration and supply agreement Immutep signed with Merck KGaA / Pfizer focused on evaluating anti-PD-L1 Bavencio (avelumab) with Immutep’s lead asset eftilagimod alpha (“efti”). 2019 will be a decisive year rich in pipeline events and we see room for significant upside from our conservative AUD0.078 target price. The company is burning c.AUD10m / year and is fully funded until YE2019E in the absence of income from a potential licensing deal. We maintain and reiterate our OUTPERFORM recommendation.

Broadest LAG-3 targeted pipeline including four distinct mechanisms of action

Since its discovery by IMM CMO / CSO Frédéric Triebel in the early 1990’s, LAG-3 has been gaining increasing attention from industry due to its potential to become the 3rd pillar in the immune checkpoint arsenal, with >10,000 patients now enrolled in clinical trials involving a LAG-3 targeted therapy. IMM’s pipeline includes two oncology-focused assets, (1) efti (Ph IIb solid cancers), a LAG-3 Ig fusion protein that binds to MHC class II on antigen-presenting cells (“APCs”) and (2) IMP701 (Ph II solid tumours), an anti-LAG-3 mAb that blocks the negative signalling on T cells thus releasing the breaks on the immune system (similar to anti-PD-1 / L1 and anti-CTLA-4 mAbs); and two assets for auto-immune disease, (3) IMP731 (Ph II ulceratice colitis), an anti-LAG-3 depleting mAb that kills auto-reactive T cells, and (4) IMP761 (preclinical), a LAG-3 stimulating mAb that down-modulates auto-reactive T cells.

Efti is the only LAG-3 targeted therapy that acts via APC stimulation

The vast majority of the LAG-3 targeted therapies in clinical development are LAG-3 blocking mAbs, such as BMS’s relatlimab and IMM’s own IMP701. Efti is the only molecule in this field that acts on the ligand, i.e. MHC class II on dendritic cells (“DC”) rather than the receptor, i.e. LAG-3 on T cells, leading to DC maturation and activation into professional APCs. This in turn leads to T cell activation via normal physiological processes and is therefore a process that can and has been shown to complement the immuno-modulatory functions of chemotherapy and blockade of other immune checkpoints. A key benefit of being used to stimulate APCs rather than to block LAG-3 on T cells means that only 2% – 3% receptor occupancy is necessary to achieve the desired effect, which has translated into a low dose of up to 30mg / patient and hence excellent safety (only transient erythema at the injection site has been observed in treated patients so far), as potentially a low cost of goods.

New clinical trial collaboration & supply agreement adds pharma partners

On 24 Sep IMM announced that it would work with Merck KGaA / Pfizer to test efti plus avelumab in advanced solid malignancies. This collaboration is similar to the one IMM already has with Merck & Co for efti, consisting in the pharma partner(s) supplying clinical trial material for a Phase I trial, which in this case will be an amendment of the ongoing investigator-led INSIGHT trial and focus on safety. Importantly, IMM retains all rights to efti and hence the ability to sign a potential licensing deal with any bidding company following Phase IIb data (AIPAC trial) for efti in HR +ve / HER2 -ve metastatic breast cancer (“mBC”) in 2019E. We remind investors that IMM already has bona fide licensing deals with Novartis (IMP701), GSK (IMP731) and EOC (efti, China only).

2019 is a decisive year rich in news flow across all pipeline assets

The most important catalyst for IMM shares is Phase IIb data from the AIPAC trial testing efti in combination with chemo (paclitaxel), which could form the basis of a conditional approval and an attractive licensing deal. The combination already led to encouraging overall response rates (“ORR”) of 47% in the 15-patient safety run-in and 50% in the 30-patient Phase I/II trial. Other pipeline events in 2019E include: (1) final data from the TACTI-mel Phase I trial in melanoma (combo with anti-PD-1 Keytruda), (2) first data from the TACTI-002 Phase II trial in lung and head & neck cancer (combo with Keytruda), and (3) first data from the Phase I INSIGHT trial. We maintain and reiterate both our OUTPERFORM recommendation and AUD0.078 target price.

Kind regards,

Brigitte de Lima | Analyst

goetzpartners Healthcare Research Team | Research Team

goetzpartners securities Limited

The Stanley Building, 7 Pancras Square, London, N1C 4AG, England, UK.

T +44 (0) 203 859 7725 | brigitte.delima@goetzpartners.com / healthcareresearch@goetzpartners.com

www.goetzpartnerssecurities.com

Registered in England No. 04684144.

Managing Directors: Dr Stephan Goetz, Martin Brunninger and Ulrich Kinzel.

Click here to see our privacy policy.

GPSL has a formal client relationship with Immutep Limited.

GPSL publishes and distributes “Investment” Research and “Corporate Sponsored” Research. Our Corporate Sponsored Research and investor meetings (e.g. NDRs, 1 to 1 meetings) are free to access and attend and is not classified as an inducement in a post-MiFID2 world, this is because the issuer is paying GPSL. GPSL does not offer any execution or market making services. This is a marketing communication as defined by the Financial Conduct Authority (“FCA”). The information herein is considered to be an acceptable minor non-monetary benefit as defined under FCA COBS 2.3A19(5).

In accordance with the General Data Protection Regulation (“GDPR“) – if you would like to be removed / unsubscribed from our CRM (also please note that you are free to contact GPSL at any time in the future to have your e-mail subscription amended), please e-mail:
researchproduction@goetzpartners.com

About GPSL: goetzpartners securities Limited is a member of the goetzpartners group, and a leading pan European investment bank and research company. We bring together a wide range of expertise, insights and innovations to advance the interests of our clients around the world. The fast-changing environment brings challenges for businesses and investors. Research innovation, digital transformation and disruptive business ideas reshuffle the corporate world at a relentless pace. Our sector knowledge and our global footprint bring together corporate intelligence and a deep understanding of the industry with a wide network of top decision makers. These collective insights help our clients to stay at the leading edge of change.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

This e-mail (including any attachments) from goetzpartners securities Limited (“GPSL”) is confidential and may contain information which is proprietary, privileged or otherwise legally protected against unauthorised use or disclosure. If you receive this e-mail in error or are not the intended recipient of this e-mail, please delete and destroy all copies in your possession, notify the sender that you have received this e-mail, and note that any review or dissemination of, or the taking of any action in reliance on this e-mail is expressly prohibited. GPSL shall not be liable for the improper or incomplete transmission of the information contained in this e-mail nor for any delay in its receipt or damage to your system. GPSL does not guarantee that the integrity of this e-mail has been maintained nor that this e-mail is free of viruses, interceptions or interference and makes no warranties in relation to these matters. This is not an offer or a solicitation to buy or sell securities or investment products, or an official confirmation. GPSL record electronic and phone communications in accordance with FCA and MiFID2 regulations, they will be monitored for regulatory and training purposes. GPSL is authorised and regulated by the Financial Conduct Authority of the United Kingdom (Firm Reference Number: 225563).

Click on the following link for the GPSL MiFID2 Investor Guidance Notice

GPSL Equity Research publications are available on the following aggregators and via news distribution circuits (For Institutional Use Only): AlphaMetry, AlphaSense, Bloomberg (GOET), Capital IQ, EQS, FACTSET, Research Tree, RNS Reach, Sentieo and Thomson Reuters.

Please copy the below link and paste it into your browser for the full pdf version of the equity research report:

https://gp.bluematrix.com/sellside/EmailDocViewer?encrypt=36751683-7dfb-4636-aa11-8240b67a4235&mime=pdf&co=gp&id=paul.dunne@goetzpartners.com&source=libraryView

 

Free to access research and investor meetings in a post-MiFID2 world.

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.

 


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

Gerresheimer AG: Micro pump for Parkinson’s treatment from Gerresheimer subsidiary Sensile Medical receives European CE declaration of conformity

DGAP-News: Gerresheimer AG / Key word(s): Market launch/Regulatory Approval

27.09.2018 / 11:02

The issuer is solely responsible for the content of this announcement.


Micro pump for Parkinson’s treatment from Gerresheimer subsidiary Sensile Medical receives European CE declaration of conformity

Duesseldorf/Olten, September 27, 2018 – A wearable micro pump from Sensile Medical has received EU certification for the European market. A European pharma company has obtained a CE declaration of conformity for the pump, which is specially designed for the treatment of Parkinson’s disease, and is now bringing it to market. This is the first time a micro pump from Gerresheimer subsidiary Sensile Medical has come into commercial use.

The micro pump is used in the treatment of advanced Parkinson’s disease. Its great benefit for patients relates to ease of use, including features such as automatic filling with liquid medicine. State-of-the-art technologies such as a color display, charging unit and data storage help enhance therapy management. The handy-sized, discreet pump comes with a leather bag for it to be worn on the user’s belt.

A prerequisite for market launch was the CE declaration of conformity for medical devices. Now it has that, the pharma company can bring the pump to market. Sensile Medical developed the micro pump for Parkinson’s disease treatment especially for the pharma company concerned. It is one of currently five concrete customer projects in various therapeutic areas.

“The CE declaration of conformity and market launch for the first micro pump, in this case for Parkinson’s treatment, marks a key milestone for our subsidiary Sensile Medical. The deservedly strict approval standards for patient-critical delivery systems of this kind are now satisfied and market launch can begin. We are correspondingly optimistic regarding further application areas for Sensile Medical’s micro pump technology,” explained Andreas Schütte, Member of the Management Board of Gerresheimer AG.

A personally programmable basal profile enables treatment to be optimized for Parkinson’s patients and ensures that they receive the precise dosage they need. Likewise for the bolus rate: A patient can cause the device to deliver a bolus at just one touch of a button. Sensile Medical’s patented SenseCore micro rotary piston pump at the heart of the pump device ensures exceptionally safe, precise drug delivery. An even greater level of safety is attained by eliminating flow rate calculations.

“In developing the micro pump for Parkinson’s treatment, we have completed a highly ambitious project to exacting requirements that improves treatment for patients. The device also comes with a large number of different languages already on board, enabling its use in many countries around the world,” explained Derek Brandt, CEO of Sensile Medical AG.

About Sensile Medical AG
Sensile Medical AG is a Swiss medical technology company established in 2004 and a subsidiary of Gerresheimer AG since 2018. In collaboration with pharmaceutical companies, Sensile Medical AG develops liquid drug delivery devices for optimal therapy. At the heart of these devices is the patented SenseCore technology. The micro pump enables highly precise dosage. Modularity and versatility are key features of the products. Sensile Medical employs around 120 people at its headquarters in Olten, Switzerland. www.sensile-medical.com

About Gerresheimer
Gerresheimer is a leading global partner to the pharma and healthcare industries. The company’s special glass and plastic products contribute to health and well-being. Gerresheimer is a global organization with about 10,000 employees and manufacturing operations in the local markets, close to customers. With plants in Europe, North and South America and Asia Gerresheimer generates revenues of approximately EUR 1.4 billion. The comprehensive product portfolio includes pharmaceutical packaging products as well as convenient and safe drug delivery systems such as insulin pens, inhalers, micro pumps, pre-fillable syringes, vials, ampoules, bottles and containers for liquid and solid pharmaceuticals with closure and safety systems, plus cosmetic packaging products.

Contact Press                                                                Contact Investor Relations
Jens Kürten                                                                   Severine Camp
Group Senior Director Communication & Marketing         Corporate Senior Director Investor Relations
Phone +49 211 6181-250                                              Phone +49 211 6181-314
Telefax +49 211 6181-241                                            Telefax +49 211 6181-121
E-Mail j.kuerten@gerresheimer.com                                 E-Mail s.camp@gerresheimer.com


27.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Germany
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-295
E-mail: s.camp@gerresheimer.com
Internet: http://www.gerresheimer.com
ISIN: DE000A0LD6E6
WKN: A0LD6E
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this

Hardman & Co Research: Allergy Therapeutics (AGY): 2018 full-year results: solid growth

Hardman & Co Research

27-Sep-2018 / 07:15 GMT/BST


Hardman & Co: 2018 full-year results: solid growth

AGY is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) Grass, the subcutaneous allergy immunotherapy (AIT), continues to gain market share despite being available in the EU only on a ‘named-patient’ basis. The Phase III trial, designed to obtain approval for PQ Birch as a biologic in Europe, is well advanced and will report data by the end of 2018. As discussed at the interim stage, underlying sales growth was affected by a low pollen season in central Europe. Full-year results suggest that this has remained a difficult market, but one in which AGY has continued to gain market share.Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/allergy-therapeutics-documents/27.09.18-2018-full-year-results-solid-growth.pdf

To contact us:

Hardman & Co
35 New Broad Street
London
EC2M 1NH
www.hardmanandco.com
Follow us on Twitter @HardmanandCo

Contacts:

Dr Martin Hall
Dr Dorothea Hill
Dr Gregoire Pave

+44 20 7194 7622

mh@hardmanandco.com
dmh@hardmanandco.com
gp@hardmanandco.com

 

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors’ understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies’ profiles across the world with high-quality research, investor engagement programmes and advisory services.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement – EQS News Service

show this

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology (news with additional features)

DGAP-News: Expedeon AG / Key word(s): Agreement

27.09.2018 / 07:30

The issuer is solely responsible for the content of this announcement.


PRESS RELEASE
27 September 2018

/

Expedeon AG signs supply agreement with Reszon Diagnostics for proprietary colloidal gold technology

 

– Expedeon’s proprietary colloidal gold to be used for manufacturing of diagnostic lateral flow assays

– Expedeon’s InnovaCoat(R) GOLD to be assessed for increasing sensitivity of marketed assays

Heidelberg, Germany and Cambridge, UK, 27 September 2018 Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has signed a three year supply agreement for its colloidal gold with Malaysia-based Reszon Diagnostics International Sdn. Bhd. (part of Revongen Corporation) (“Reszon”), a developer and manufacturer of innovative in vitro diagnostics (IVD) rapid test kits, and ELISA kits. Reszon operates globally covering Asia, Middle East, sub-Saharan Africa, and the USA.

Under the terms of the agreement, Expedeon will supply Reszon with its proprietary colloidal gold, an aqueous suspension of spherical metallic nanoparticles manufactured to the highest standard, providing high efficiency antibody binding for maximum sensitivity. Reszon will use the gold nanoparticles for manufacturing of its diagnostic lateral flow assays (LFAs). The company will also be testing Expedeon’s InnovaCoat(R) GOLD nanoparticles, to increase the sensitivity of LFA which are already on the market. InnovaCoat(R) GOLD nanoparticles have a proprietary surface coating which covalently binds antibodies or proteins to form highly stable conjugates. The technology is fully scalable and stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.

Dr. Heikki Lanckriet, CEO and CSO of Expedeon, commented: “This agreement is the second just this month for our colloidal gold in Asia, further validating Expedeon as a global supplier for the diagnostics industry. The adoption of our colloidal gold and InnovaCoat(R) GOLD products by Reszon Diagnostics exemplifies the increased reach Expedeon is seeing as a key provider of materials and services to the diagnostics industry. We are confident that this represents the start of a successful and expanding relationship with Reszon and its parent company Revongen.”

For a high resolution image, please contact MC Services or Zyme Communications.

For further information, please contact:

Expedeon AG
Dr. Heikki Lanckriet
CEO/CSO
Phone: +44 1223 873 364
Email: heikki.lanckriet@expedeon.com
Investor website: www.investors.expedeon.com

MC Services AG (Investor Relations and International Media Relations)
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 0
Email: expedeon@mc-services.eu
Zyme Communications (Trade and UK Media Relations)
Katie Odgaard
Phone: +44 (0)7787 502 947
Email: katie.odgaard@zymecommunications.com

About Expedeon AG: www.expedeon.com
Expedeon is an enabler of exciting advances in medical science and patient care. The Company’s core technologies, innovative products and services are used in research laboratories around the world, enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon’s technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers’ development and commercialisation objectives. Expedeon’s products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

### This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###


Additional features:

Document: http://n.eqs.com/c/fncls.ssp?u=HGOKJJWAHW
Document title: Res_Eng


27.09.2018 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Expedeon AG
Waldhofer Str. 102
69123 Heidelberg
Germany
Phone: +49 (0) 6221 3540 125
Fax: +49 (0) 6221 3540 127
E-mail: investors@expedeon.com
Internet: www.expedeon.com
ISIN: DE000A1RFM03
WKN: A1RFM0
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange

 
End of News DGAP News Service

show this